 |
|
 |
|
 |
|
Program |
Partnership |
Call to |
Friday May 14th |
|
08:30 am |
•
•
•
•
• |
R3i Symposium Lipid-related residual vascular risk. Opening the new era of vascular prevention Introduction Fighting the residual vascular risk: time has come to act ! Fruchart Jean-Charles (France) Reducing the residual vascular risk: lessons from recent studies ARBITER 6 - HALTS: settings the stage for an effective residual macrovascular risk management strategy Sacks Frank (USA) ACCORD: a pharmacological approach to macrovascular and microvascular risk reduction in patients with diabetes Ginsberg Henry (USA) The R3i REALIST studies: a worldwide epidemiological approach to lipid-related residual risk Exploring the association between atherogenic dyslipidemia and macrovascular residual risk: results from pilot centers Sacks Frank (USA) Exploring the association between atherogenic dyslipidemia and microvascular residual risk: results from pilot centers Hermans Michel (Belgium) Discussion and wrap-up |
10:30 am |
|
Coffee break |
11:00 am |
•
•
• |
Symposium sponsored by KOWA Future therapeutic approaches for atherosclerosis Chair: Kita Toru (Japan) From the dawn of the statin era to the present day Matsuzawa Yuji (Japan) What are we looking for in a statin today and what are the future steps ? Corsini Alberto (Italy) Impact of nanotechnology-based selective delivery of pitavastatin for the development of innovative treatment of ischemic cardiovascular diseases Egashira Kensuke (Japan) |
12:30 pm |
|
Lunch |
02:00 pm |
•
•
• |
ACADEMIC SESSION III Lifestyle and exercise versus medical therapies in prevention and management of the metabolic syndrome Chair: Sacks Frank (USA) Lifestyle and CHD prevention with particular focus on nutrition. Yesterday, today and tomorrow Farinaro Eduardo (Italy) Epigenomics and metabolic syndrome Kodama Tatsuhiko (Japan) New approaches in the treatment of diabetic dyslipidemia Carmena Rafael (Spain) |
03:30 pm |
|
Coffee Break |
04:00 pm |
•
•
• |
ACADEMIC SESSION IV Metabolic dyslipoproteinemia and atherosclerosis Chair: Davignon Jean (Canada) Managing dyslipidemia in developing countries: problems and possbilities Sadikot Shaukat M. (India) What is the priority in cardiometabolic risk treatment ? Ceska Richard (Czek Republic) HDL infusions in the treatment of the high risk patient with cardiovascular disease Brewer Bryan (USA) |
